Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)Roger von Moos, Arnoud J. Templeton, Andreas Müller et al.|Annals of Oncology|2018Cited by 4
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)AMANDA OLGA MÜLLER, Roger von Moos, AJ Templeton et al.|Cancer Research|2019Cited by 2